Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
Zevra Therapeutics (ZVRA), a commercial-stage company specializing in rare disease therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 11, 2025. The company will release its financial results after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
Investors can access the webcast through Zevra's investor relations website, with dial-in options available for both U.S. (800-245-3047) and international (+1-203-518-9765) participants using Conference ID: ZVRAQ424. A replay of the webcast will be available for 90 days following the presentation.
Zevra Therapeutics (ZVRA), un'azienda in fase commerciale specializzata nelle terapie per malattie rare, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per martedì 11 marzo 2025. L'azienda pubblicherà i risultati finanziari dopo la chiusura del mercato, seguiti da una conferenza telefonica e una trasmissione audio in diretta alle 16:30 ET.
Gli investitori possono accedere alla trasmissione tramite il sito web delle relazioni con gli investitori di Zevra, con opzioni di accesso telefonico disponibili sia per i partecipanti statunitensi (800-245-3047) che internazionali (+1-203-518-9765) utilizzando l'ID conferenza: ZVRAQ424. Una registrazione della trasmissione sarà disponibile per 90 giorni dopo la presentazione.
Zevra Therapeutics (ZVRA), una empresa en etapa comercial especializada en terapias para enfermedades raras, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para martes 11 de marzo de 2025. La compañía publicará sus resultados financieros después del cierre del mercado, seguido de una llamada de conferencia y una transmisión de audio a las 4:30 p.m. ET.
Los inversores pueden acceder a la transmisión a través del sitio web de relaciones con inversores de Zevra, con opciones de marcación disponibles tanto para participantes de EE. UU. (800-245-3047) como internacionales (+1-203-518-9765) utilizando el ID de conferencia: ZVRAQ424. Una repetición de la transmisión estará disponible durante 90 días después de la presentación.
Zevra Therapeutics (ZVRA), 희귀 질환 치료에 전문화된 상업 단계 회사가 2025년 3월 11일 화요일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 시장 마감 후 재무 결과를 발표하고, 오후 4시 30분 ET에 컨퍼런스 콜 및 오디오 웹캐스트를 진행할 예정입니다.
투자자들은 Zevra의 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 미국 (800-245-3047) 및 국제 (+1-203-518-9765) 참여자를 위한 전화 접속 옵션이 제공됩니다. 회의 ID: ZVRAQ424. 발표 후 90일 동안 웹캐스트 재생이 가능합니다.
Zevra Therapeutics (ZVRA), une entreprise en phase commerciale spécialisée dans les thérapies pour les maladies rares, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour mardi 11 mars 2025. L'entreprise publiera ses résultats financiers après la fermeture des marchés, suivis d'une conférence téléphonique et d'un webinaire audio à 16h30 ET.
Les investisseurs peuvent accéder au webinaire via le site des relations investisseurs de Zevra, avec des options de composition disponibles pour les participants américains (800-245-3047) et internationaux (+1-203-518-9765) en utilisant l'ID de conférence : ZVRAQ424. Une rediffusion du webinaire sera disponible pendant 90 jours après la présentation.
Zevra Therapeutics (ZVRA), ein Unternehmen in der kommerziellen Phase, das sich auf Therapien für seltene Krankheiten spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Dienstag, den 11. März 2025 angesetzt. Das Unternehmen wird seine finanziellen Ergebnisse nach Börsenschluss veröffentlichen, gefolgt von einer Telefonkonferenz und einem Audio-Webcast um 16:30 Uhr ET.
Investoren können auf den Webcast über die Investor-Relations-Website von Zevra zugreifen, mit Einwahlmöglichkeiten sowohl für US-Teilnehmer (800-245-3047) als auch für internationale Teilnehmer (+1-203-518-9765) unter Verwendung der Konferenz-ID: ZVRAQ424. Eine Wiederholung des Webcasts wird 90 Tage nach der Präsentation verfügbar sein.
- None.
- None.
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET
CELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2024 on Tuesday, Mar. 11, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/.
To join via telephone, please use the following dial-in information:
- (800) 245-3047 (United States)
- +1 (203) 518-9765 (International)
- Conference ID: ZVRAQ424
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page of Zevra’s website at https://investors.zevra.com/.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended Sept. 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
FAQ
When will Zevra Therapeutics (ZVRA) release its Q4 2024 earnings?
How can investors access ZVRA's Q4 2024 earnings call?
How long will ZVRA's Q4 2024 earnings call replay be available?
What time is ZVRA's Q4 2024 earnings conference call?
